Abstract
•Treatment or prevention of gynecologic cancer often results in induced menopause significantly impacting quality of life. •Hormone therapy is underutilized in in these settings despite more severe symptoms with induced menopause. •The risk/benefit profile of HT is favorable in most EOC, early stage endometrial, and cervical cancer. •HT is not recommended in women with advanced EC, uterine sarcoma, endometrioid or low grade serous ovarian cancer. •Lynch syndrome patients and BRCA mutation carriers without history of breast cancer may also use HT to improve QOL.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.